NVO Just Fumbled – Here’s Who Picks up The Ball

This biotech giant could capture a bigger chunk of a $150B market.‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

"NVO just handed LLY a major win – and I think the market hasn't fully priced it in yet." Bryan Bottarelli, Co-Founder, Monument Traders Alliance Nvidia. Google. Microsoft. The AI trade minted fortunes over the last three years. But in 2026, I believe that trade is finally running out of road… for everyone except the most fundamentally sound companies involved in AI. The reason is simple: AI is getting expensive. The infrastructure bill is coming due. With data centers alone projected to require $6.7 trillion in compute spending by 2030. When one sector like AI gets too pricey, money looks for a new place to go. And with AI accelerating drug discovery and clinical data analysis, I believe the biotech/healthcare sector is the logical place for money to land next. (My Monument Trend Advisory subscribers know this... we focused on the sector in our February issue, along with three biotech recommendations.) One biotech group I'm watching right now is Eli Lilly (LLY). Here's why I like LLY for a potential trade…. Yesterday morning, shares of rival biotech group Novo Nordisk (NVO) were down 15% after the company's latest weight loss drug, CagriSema, failed to match Eli Lilly's tirzepatide in a head-to-head trial. Obesity and metabolic drugs are already a $100-150 billion annual market – and it's still in the early innings. What's bad news for NVO is fantastic news for LLY - as this solidifies their GLP-1 drug as the best in class - and further establishes their leadership position for new patients. Overall, LLY could become one of the largest cash flow machines in healthcare. SPONSORED The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion. Click here to see the Tesla shock that could blindside everyone. Action Plan: I believe LLY could be in for a short-term spike with rival NVO coming up short in its latest drug trial. It's on my watchlist for a trade right now in The War Room. My colleague Karim also recently revealed a fundamentally sound company that could completely revolutionize AI – and few people have heard of it. Click here to unlock this play today. SPONSORED See THIS Spike BEFORE Earnings = BIG Move on Earnings One spike the day BEFORE earnings... could have led to top overnight gains like: 122% on Dick's Sporting Goods... 251% on Chewy... 139% on Best Buy... 92% on Oracle... 158% on FedEx 129% on Dutch Bros... and many more. Whether the stock surges... or crashes... With a big move... these trades can make HUGE gains! Discover The Simple Pre-Earnings Spike Monument Traders Alliance, LLC   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2026 Monument Traders Alliance, LLC | All Rights Reserved       Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201. REF: 000133481441